Chiu S, Paulose C S, Mishra R K
Science. 1981 Dec 11;214(4526):1261-2. doi: 10.1126/science.6117947.
An animal model of tardive dyskinesia was used to evaluate the potential antidyskinetic properties of the neuropeptide L-prolyl-L-leucyl-glycinamide (PLG). In rats, PLG administered concurrently with the neuroleptic drug haloperidol or chlorpromazine antagonized the enhancement of specific [3H]spiroperidol binding in the striatum that is associated with long-term neuroleptic treatment. The results are discussed in relation to a possible functional coupling of the putative PLG receptor with neuroleptic-dopamine receptor complex and clinical implications for tardive dyskinesia.
采用迟发性运动障碍动物模型来评估神经肽L-脯氨酰-L-亮氨酰-甘氨酰胺(PLG)的潜在抗运动障碍特性。在大鼠中,PLG与抗精神病药物氟哌啶醇或氯丙嗪同时给药时,可拮抗纹状体中与长期抗精神病治疗相关的特异性[3H]螺哌啶醇结合增强现象。结合假定的PLG受体与抗精神病药物-多巴胺受体复合物的可能功能偶联以及迟发性运动障碍的临床意义对结果进行了讨论。